Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

CanSino’s, J&J’s Covid-19 vaccines may be stifled by pre-existing antibodies while AstraZeneca’s, ReiThera’s may need booster

23 Jun 2020 (Last Updated June 23rd, 2020 15:53)

Notwithstanding its benefits over other vaccine technologies for Covid-19, adenovirus vector vaccines could be tripped up by pre-existing antibodies to the vectors used and the requirement for a second injection to increase protection.

CanSino Biologics’ Ad5-nCoV and Johnson & Johnson’s AdVac platform-based vaccine use a human adenovirus vector, but a notable portion of individuals may already have neutralising antibodies against the vector, reducing efficacy prospects. Read more here.